EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Passing the torch: The ascendance of the glutamatergic synapse in the pathophysiology of schizophrenia

Joseph T Coyle

Biochemical Pharmacology · 2024

DOI: 10.1016/j.bcp.2024.116376 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Joseph T Coyle. Beteiligte Einrichtung: Eben S Draper Professor of Psychiatry and Neuroscience Harvard Medical School (Emeritus), McLean Hospital, 115 Mill St, Belmont, MA 02478, United Sta…. Hauptthemen laut MEDLINE: Schizophrenia, Synapses, Glutamic Acid. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 77 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For nearly fifty years, the dopamine hypothesis has dominated our understanding of the pathophysiology of schizophrenia and provided the lone target for drug development. However, with the exception of clozapine, the dopamine D2 receptor antagonizing anti-psychotic drugs have little impact on the negative symptoms and cognitive deficits, aspects of the disorder that robustly predict outcome. Pathologic studies reveal cortical atrophy and wide-spread loss of glutamatergic synaptic spines, unexplained by dopaminergic malfunction. Recent genome-wide association studies indicate that at least thirty risk genes for schizophrenia encode proteins localized to the glutamatergic synapse and inhibit glutamate neurotransmission, especially at the NMDA receptor. To function, the NMDA receptor requires the binding of glycine (primarily in the cerebellum and brainstem) or D-serine (in forebrain) to the NR1 channel subunit of the NMDA receptor. Genetically silencing the gene (srr) encoding serine racemase, the biosynthetic enzyme for D-serine, results in forebrain NMDA receptor hypofunction. The srr-/- mice have 90 % loss of endogenous D-serine and approximately 70 % decrease in NMDA receptor function. Several animal models of schizophrenia are based on behavioral and pharmacologic strategies, which have negligible validity with regard to the fundamental etiology of schizophrenia. We summarize here the results of a mouse model, in which srr, one of the two dozen or more risk gene for schizophrenia that affect NMDA receptor function, has been inactivated. The srr-/- mice exhibit striking similarities to schizophrenia including cortical atrophy, loss of cortico-limbic glutamatergic synapses, increased sub-cortical dopamine release, EEG abnormalities, and cognitive impairments. The limited efficacy of drugs targeting the glutamatergic synapse on DSM-5 diagnosed criteria for schizophrenia used in clinical trials may reflect the fact that only 30 % of the patients have impaired glutamatergic neurotransmission, resulting from the genetic heterogeneity of the disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaSynapsesGlutamic AcidAnimalsHumansReceptors, N-Methyl-D-AspartateMiceDopamine

Stichwörter der Autor:innen

Anti-psychotic drugsD-SerineDopamineGenome-Wide Association StudiesGlutamateSchizophreniaSerine Racemase

Substanzen

Glutamic AcidReceptors, N-Methyl-D-AspartateDopamine

Autor:innen und Institutionen

  • Eben S Draper Professor of Psychiatry and Neuroscience Harvard Medical School (Emeritus), McLean Hospital, 115 Mill St, Belmont, MA 02478, United States. Electronic address: joseph_coyle@emeritus.hms.harvard.edu.

Zitieren

APA

Coyle, J. T. (2024). Passing the torch: The ascendance of the glutamatergic synapse in the pathophysiology of schizophrenia. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116376

Vancouver

Coyle JT. Passing the torch: The ascendance of the glutamatergic synapse in the pathophysiology of schizophrenia. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116376

BibTeX
@article{Coyle2024,
  author = {Coyle, Joseph T},
  title = {Passing the torch: The ascendance of the glutamatergic synapse in the pathophysiology of schizophrenia},
  journal = {Biochemical Pharmacology},
  year = {2024},
  doi = {10.1016/j.bcp.2024.116376}
}
Kostenlos starten →